Related references
Note: Only part of the references are listed.Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
Sisi Yang et al.
FRONTIERS IN MEDICINE (2021)
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir
Nobuharu Tamaki et al.
JGH OPEN (2020)
Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan
Fumitaka Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial
Ayako Iida-Ueno et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study
Jonggi Choi et al.
JAMA ONCOLOGY (2019)
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues
Terry Cheuk-Fung Yip et al.
JOURNAL OF HEPATOLOGY (2019)
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
Kazumoto Murata et al.
GUT (2018)
Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients
Kazuhiko Koike et al.
HEPATOLOGY RESEARCH (2018)
Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial
H. J. Yim et al.
JOURNAL OF VIRAL HEPATITIS (2018)
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B
Darren Wong et al.
LIVER INTERNATIONAL (2018)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities
Robert G. Gish et al.
ANTIVIRAL RESEARCH (2015)
Impact of Long-Term Tenofovir Disoproxil Fumarate on Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
W. Ray Kim et al.
CANCER (2015)
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients
Michelle Martinot-Peignoux et al.
LIVER INTERNATIONAL (2015)
Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment
Wai-Kay Seto et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients
T. Hara et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B
Min-Ran Li et al.
PLOS ONE (2014)
Short- and long-term outcome of interferon therapy for chronic hepatitis B infection
Yasushi Seo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment
Wai-Kay Seto et al.
JOURNAL OF HEPATOLOGY (2013)
Progressive Renal Tubular Dysfunction Associated with Long-Term Use of Tenofovir DF
Ei Kinai et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
